ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 0152

Pm/Scl Patients Have an Expanded Population of CD19+CD21lo/negCD11c+CD11b+ Cells Expressing a Monocyte, Not B Cell, Transcriptome

Erin Wilfong, Leslie Crofford and Rachel Bonami, Vanderbilt University Medical Center, Nashville, TN

Meeting: ACR Convergence 2022

Keywords: B-Lymphocyte, Monocytes/macrophages, Myositis

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Saturday, November 12, 2022

Title: Muscle Biology, Myositis and Myopathies Poster I

Session Type: Poster Session A

Session Time: 1:00PM-3:00PM

Background/Purpose: CD19 is considered a canonical B cell lineage marker. Previously, we have reported that CD19+CD21lo/negCD11c+ cells were increased in both systemic sclerosis [PMC8828801] as well as one immune endotype of inflammatory myositis expressing the Pm/Scl+ autoantibody [PMC8964392]. These cells did not express traditional B cell surface markers such as IgD, IgM, CCR4, or CCR6 but expressed the monocyte markers CX3CR1, CD11b, and CD11c. Single cell RNA-seq was performed to determine whether this CD19+ cell population was of B cell lineage.

Methods: Peripheral blood mononuclear cells were collected via venipuncture, isolated using CPT tubes, and cryopreserved (VUMC IRB 141415). Five +Pm/Scl patients and five healthy control samples were stained with the Total-Seq C human cocktail, and live CD19+CD3- cells were isolated via fluorescence activated cell sorting. Cells underwent RNA-seq (transcriptomic), CITE-seq (phenotypic), and BCR-seq (immune repertoire) profiled using the single cell, 10X genomics platform. Resulting data were processed using CellRanger and analyzed using a custom Seurat-based pipeline.

Results: Table 1 shows participant demographics and clinical features. The final analysis included 10,175 healthy and 13,864 +Pm/Scl live CD19+ cells. Figure 1 shows a UMAP with Seurat-identified clusters based on transcriptional similarity. Cluster 11 (light blue circle) corresponds to our previously identified CD19+CD21lo/negCD11c+ population. Notably, this population did not express immunoglobulin genes but expressed several monocyte genes including LST1, AIF1 (upregulated in rheumatoid arthritis monocytes), and TIMP1 (upregulated in systemic sclerosis monocytes). Based on these results, the CD19+CD21lo/negCD11c+ was identified as monocyte– not B cell – lineage.

Conclusion: The CD19+CD21loCD11c+ population identified in Pm/Scl+ IIM patients represents a monocyte population. This finding underscores the importance of combining transcriptional and surface marker analysis in immune profiling. Furthermore, this expanded population may contribute to clinical features shared between SSc and Pm/Scl+ IIM.

Supporting image 1

Supporting image 2


Disclosures: E. Wilfong, Boehringer-Ingelheim, Department of Justice/Health and Human Services - Vaccine Injury Compensation Program; L. Crofford, None; R. Bonami, Boehringer-Ingelheim.

To cite this abstract in AMA style:

Wilfong E, Crofford L, Bonami R. Pm/Scl Patients Have an Expanded Population of CD19+CD21lo/negCD11c+CD11b+ Cells Expressing a Monocyte, Not B Cell, Transcriptome [abstract]. Arthritis Rheumatol. 2022; 74 (suppl 9). https://acrabstracts.org/abstract/pm-scl-patients-have-an-expanded-population-of-cd19cd21lo-negcd11ccd11b-cells-expressing-a-monocyte-not-b-cell-transcriptome/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2022

ACR Meeting Abstracts - https://acrabstracts.org/abstract/pm-scl-patients-have-an-expanded-population-of-cd19cd21lo-negcd11ccd11b-cells-expressing-a-monocyte-not-b-cell-transcriptome/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology